- Home
- EYE vs CDTX Comparison
EYE vs CDTX Comparison
Compare EYE & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EYE
- CDTX
- Stock Information
- Founded
- EYE 1990
- CDTX 2012
- Country
- EYE United States
- CDTX United States
- Employees
- EYE N/A
- CDTX N/A
- Industry
- EYE Ophthalmic Goods
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EYE Health Care
- CDTX Health Care
- Exchange
- EYE Nasdaq
- CDTX Nasdaq
- Market Cap
- EYE 1.9B
- CDTX 1.7B
- IPO Year
- EYE 2017
- CDTX 2015
- Fundamental
- Price
- EYE $23.48
- CDTX $63.17
- Analyst Decision
- EYE Buy
- CDTX Strong Buy
- Analyst Count
- EYE 9
- CDTX 11
- Target Price
- EYE $21.78
- CDTX $57.00
- AVG Volume (30 Days)
- EYE 2.2M
- CDTX 430.9K
- Earning Date
- EYE 08-06-2025
- CDTX 08-07-2025
- Dividend Yield
- EYE N/A
- CDTX N/A
- EPS Growth
- EYE N/A
- CDTX N/A
- EPS
- EYE N/A
- CDTX N/A
- Revenue
- EYE $1,885,540,000.00
- CDTX N/A
- Revenue This Year
- EYE $8.92
- CDTX N/A
- Revenue Next Year
- EYE $3.32
- CDTX N/A
- P/E Ratio
- EYE N/A
- CDTX N/A
- Revenue Growth
- EYE 5.08
- CDTX N/A
- 52 Week Low
- EYE $9.56
- CDTX $10.14
- 52 Week High
- EYE $25.67
- CDTX $69.36
- Technical
- Relative Strength Index (RSI)
- EYE 49.22
- CDTX 51.89
- Support Level
- EYE $21.51
- CDTX $60.97
- Resistance Level
- EYE $25.05
- CDTX $67.00
- Average True Range (ATR)
- EYE 0.88
- CDTX 3.42
- MACD
- EYE -0.08
- CDTX -0.72
- Stochastic Oscillator
- EYE 55.65
- CDTX 35.25
About EYE National Vision Holdings Inc.
National Vision Holdings Inc is an optical retailer in the U.S. Its product portfolio includes eyeglasses and sunglasses, contact lenses, accessories, and other products. The company has two operating segments; Owned and Host segment includes company-owned brands America's Best and Eyeglass World, In America's Best stores, vision care services are provided by optometrists or by independent professional corporations and Host operating consist of Military and Fred Meyer which provide eye exams by independent optometrists, and the Legacy segment manages the operations of, and supplies inventory and lab processing services to Legacy retail Vision Centers. It earns a majority of its revenue from the Owned and Host segment.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.